Zhejiang Hisun Pharmaceutical (600267.SH) releases a forecasted profit, estimating a net profit of 570-630 million yuan in 2024, turning losses into profits.
Guangzhou Pharmaceuticals Corporation (stock code: 600267.SH) announced that the company is expected to achieve attributable net profit to shareholders of the listed company for the year 2024...
Zhejiang Hisun Pharmaceutical (600267.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 570 million to 630 million yuan in 2024, compared to a loss in the same period last year.
Related Articles
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
